In PNAS, Demas et al. ([@r1]) show, by long-term in vitro selection using culture-adapted *Plasmodium falciparum* isolates from Senegal, that the gene encoding the actin-binding protein *P. falciparum* coronin (*pfcoronin*) and its genetic variants (G50E, R100K, and E107V) can reduce the susceptibility of the parasite to the active metabolite of the fast-acting antimalarial drug artemisinin, dihydroartemisinin (DHA). Resistance to artemisinins is a global threat in malaria control and elimination efforts ([@r2]).

Artemisinin resistance, first reported in Southeast Asia and still extremely rare, was associated with the *P. falciparum Pf*Kelch13-propeller domain (*kelch13* mutations: Y493H, R539T, I543T, and C580Y) ([@r3]). *Pf*Coronin, which is structurally similar to Kelch13, is believed to interact with F-actin via its N-terminal propeller domain and to mediate actin organization and motility in merozoites and sporozoites ([@r4], [@r5]). The worldwide map of the occurrence of *kelch13*, however, indicates absence of the Asian artemisinin-resistance alleles in Africa ([@r6][@r7]--[@r8]). So far, it is not clear whether the *pfcoronin* variants G50E, R100K, and E107V occur in natural *P. falciparum* populations---in particular, in clinical isolates from Africa.

We looked at a total of 353 *P. falciparum* patient isolates that were earlier characterized for the absence of *kelch13* gene mutations ([@r7][@r8][@r9]--[@r10]) from 4 African countries to verify whether these isolates carry the *pfcoronin* mutations G50E, R100K, and E107V, which were described by Demas et al. ([@r1]) to be associated with reduced susceptibility to DHA. A total of 297 samples were successfully genotyped by direct Sanger sequencing. Details of the study groups from Gabon (*n* = 102), Congo (*n* = 48), Ghana (*n* = 57), and Kenya (*n* = 90) are described elsewhere ([@r7][@r8][@r9]--[@r10]). The *pfcoronin* mutations G50E, R100K, and E107V were not observed at all among the isolates. However, 14 distinct mutations, including several nonsynonymous substitutions, were identified in the *pfcoronin* exon-3 ([Table 1](#t01){ref-type="table"}). None of the isolates carried the Asian *kelch13* resistance alleles M476I, Y493H, R539T, I543T, and C580Y. The mutation P76S (DNA position C562T) was observed to be most frequent (\>10%) among isolates from central and west Africa. There was no indication of artemisinin or artemisinin-based combination therapy resistance in these patients. The functional role of the observed *pfcoronin* P76S needs to be elucidated among central and west African *P. falciparum* isolates.

###### 

*pfcoronin* mutations observed in 4 African countries

  Amino acid change   SNP position   Gabon, *n* (%) (*n* = 102)   Ghana, *n* (%) (*n* = 57)   Kenya, *n* (%) (*n* = 90)   Congo, *n* (%) (*n* = 48)   Total, *n* (%) (*N* = 297)
  ------------------- -------------- ---------------------------- --------------------------- --------------------------- --------------------------- ----------------------------
  I53I                C495T          0                            1 (2)                       0                           0                           1 (0.3)
  V62M                G520A          1 (1)                        1 (2)                       0                           0                           2 (0.7)
  K69K/I/R            A542A/T/G      0                            3 (5)                       0                           11 (23)                     14 (5)
  P76S                C562T          11 (11)                      9 (16)                      4 (4)                       8 (17)                      32 (11)
  N110N/Y/D           A664A/T/G      0                            1 (2)                       0                           5 (10)                      6 (2)
  N112N/Y/D           A670A/T/G      0                            0                           0                           1 (2)                       1 (0.3)
  K115K/stop/E        A679A/T/G      0                            0                           0                           1 (2)                       1 (0.3)
  L121L/F/L           A699A/T/G      0                            0                           0                           1 (2)                       1 (0.3)
  K127K/stop/E        A715A/T/G      0                            0                           0                           1 (2)                       1 (0.3)
  K127K/I/R           A716A/T/G      0                            0                           0                           5 (10)                      5 (2)
  V128V               A720A/T/G      0                            0                           0                           1 (2)                       1 (0.3)
  N134N/Y/D           A736A/T/G      0                            0                           0                           4 (8)                       4 (1)
  N137N/Y/D           A745A/T/G      0                            0                           0                           10                          10 (3)
  N137N/I/S           A746A/T/G      0                            0                           0                           2 (4)                       2 (0.7)

SNP, single nucleotide polymorphism.

Much effort has been made in recent years to determine the genetic basis of artemisinin resistance, which still remains unclear to a large extent. There is an obvious difference in occurrence of *pfkelch13* and *pfcoronin* alleles between Asia and Africa, which may also cause differences in parasite clearance rates during treatment with artemisinin-containing antimalarial combinations. However, we should bear in mind that parasite clearance rate or failure of an artemisinin-containing antimalarial is also, and even most often, determined by the activity of the partner drug, such as lumefantrine, amodiaquine, piperaquine, and pyronaridine.
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